Sio Gene Therapies, Inc.
(NASDAQ : AXGT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.68%337.110.0%$4577.21m
NVAXNovavax, Inc. -0.06%166.1579.4%$747.41m
BNTXBioNTech SE 3.86%271.170.0%$732.01m
AMGNAmgen, Inc. 0.93%205.011.4%$543.23m
SNSSSunesis Pharmaceuticals, Inc. 0.96%6.320.7%$441.79m
REGNRegeneron Pharmaceuticals, Inc. 1.83%553.402.7%$427.22m
GILDGilead Sciences, Inc. 0.98%66.541.0%$411.79m
CCXIChemoCentryx, Inc. 3.84%33.682.9%$400.05m
ILMNIllumina, Inc. 0.09%410.903.3%$375.00m
XLRNAcceleron Pharma, Inc. 0.22%173.385.3%$363.25m
VRTXVertex Pharmaceuticals, Inc. 1.84%184.121.9%$263.01m
BIIBBiogen, Inc. 0.38%270.761.7%$234.55m
OCGNOcugen, Inc. 2.06%8.430.0%$182.22m
XENEXenon Pharmaceuticals, Inc. 0.13%30.760.4%$171.97m
CRSPCRISPR Therapeutics AG 5.51%101.520.6%$162.72m

Company Profile

Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in New York, NY.